| palbociclib based treatment |
| palbociclib plus endocrine therapy | palbociclib plus letrozole |
| la/mBC - HR-positive - 1st line (L1) 13 | | |
| la/mBC - HR positive - L1 - PIK3CA mutant 1 | | |
Comparator:
vs endocrine therapy; vs letrozole;
Risk of bias:
low;
some concerns;
high;
NA;